FDA
-
-
-
-
-
-
-
BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes
-
-
-
-
-
-
-
BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes
-
-
-
-
-
-
-
BioStem Showcasing its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Fall Meeting
-
-
-
-
-
-
-
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
-
-
-
-
-
-
-
BioStem Announces Notice of Allowance for Three New U.S. Patent Applications
-
-
-
-
-
-
-
BioStem Technologies to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on April 14, 2025
-
-
-
-
-
-
-
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

